MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV,Bioorganic & Medicinal Chemistry Letters

当前位置： X-MOL 学术 › Bioorg. Med. Chem. Lett. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV
Bioorganic & Medicinal Chemistry Letters ( IF 2.5 ) Pub Date : 2018-03-20 , DOI: 10.1016/j.bmcl.2018.03.049
Anilkumar G Nair ₁ , Qingbei Zeng ₁ , Oleg Selyutin ₁ , Stuart B Rosenblum ₁ , Yueheng Jiang ₁ , De-Yi Yang ₁ , Kerry Keertikar ₁ , Guowei Zhou ₁ , Michael Dwyer ₁ , Seong Heon Kim ₁ , Bandarpalle Shankar ₁ , Wensheng Yu ₁ , Ling Tong ₁ , Lei Chen ₁ , Robert Mazzola ₁ , John Caldwell ₁ , Haiqun Tang ₁ , Sony Agrawal ₁ , Rong Liu ₁ , Rong Kong ₁ , Paul Ingravallo ₁ , Ellen Xia ₁ , Ying Zhai ₁ , Amin Nomeir ₁ , Ernest Asante-Appiah ₁ , Joseph A Kozlowski ₁

Affiliation

HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination regimen. Herein, we describe the discovery and characterization of silyl proline-containing HCV NS5A inhibitor MK-8325 with good pan-genotype activity and acceptable pharmacokinetic properties.

中文翻译：